Revive Therapeutics Ltd., a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, has entered into a non-binding letter of intent (LoI) to acquire the full rights to DiagnaMed Holdings Corp.’s intellectual property pertaining to molecular H₂ as potential treatments for neurological and mental health disorders. The acquired assets will include all of the following:

• Provisional patent application with the U.S. Patent and Trademark Office outlining pharmaceutical-based methods and compositions for producing molecular H₂ as potential treatments for neurological and mental health disorders. The patent application, entitled “Methods and Compositions for Producing H₂ for Treating Diseases and Disorders Affecting Brain Health,” outlines novel combinations of certain pharmaceutical-grade H₂ producing ingredients as a potential therapeutic option for a variety of neurological disorders such as, but not limited to, Dementia, Parkinson’s disease, and Traumatic brain injury, and mental health disorders including, Depression, Anxiety, and Post-traumatic stress disorder (press release).
• All intellectual and work property derived from DiagnaMed’s research activities in amyotrophic lateral sclerosis (ALS) and its Orphan Drug Designation (ODD) for molecular H₂ in the treatment of ALS by the U.S. Food and Drug Administration (FDA).

Michael Frank, CEO of Revive, commented, “We are excited about advancing the clinical development of molecular H₂ for brain disorders, specifically as a potential treatment for ALS. The orphan drug designation granted by the FDA for molecular H₂ in ALS offers hope to patients and families impacted by this debilitating illness. We are committed to collaborating with leading ALS researchers, patient advocacy groups, and regulatory experts to ensure a rigorous and expedited path toward potential approval.”

ALS is a progressive neuromuscular disease that attacks nerve cells responsible for controlling voluntary muscle movement, leading to paralysis and, ultimately, respiratory failure, and has a life expectancy of only two to six years after diagnosis. Currently, there is no known cure for ALS. ALS affects approximately 50,000 people in the U.S. and Europe, with over 5,000 new cases diagnosed annually. With limited treatment options available, the FDA’s recognition of molecular H₂ as an orphan drug offers hope to patients and families impacted by this debilitating illness.

Molecular H₂, a small molecule with antioxidant and anti-inflammatory properties, has shown early promise in preclinical studies for its ability to mitigate oxidative stress and inflammation—key factors implicated in ALS progression. The FDA’s decision paves the way for Revive to accelerate its development programs with molecular H₂.

The final terms of the Acquisition will be agreed to by the parties after the completion of due diligence by Revive. The Acquisition is expected to close on or before March 31, 2025, subject to customary closing conditions, including but not limited to, the negotiation and execution of a definitive agreement.

Revive also announces that it has entered into a promissory note with an arm’s length private lender pursuant to which Revive has received a loan in the principal amount of $65,000 to assist with current working capital needs. The loan amount matures on February 19, 2026, bears interest at a rate of 8% per annum, and is secured by way of a general security agreement.